Clinical trials: Idarubicin
Acute Promyelocytic Leukemia
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Primary objectives To evaluate the efficacy and toxicity of a risk-adapted protocol that use idarubicin for induction and consolidation therapy in patients with APL.
- Trial name
- NCT00408278
- Testing
- ATRA, Idarubicina, Mitoxantrone
- Where
- 42 sites in Poland, Spain and 1 more
- Volunteers
- 300 people
- Sponsor
- PETHEMA Foundation
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is among the most common hematologic malignancies in adults and accounts for approximately 10,000 deaths in the United States every year. AML is commonly diagnosed in sixth or seventh decades of life.
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT03226418
- Testing
- Cytarabine, Decitabine, Idarubicin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
Leukemia, Myelodysplastic Syndromes
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00077116
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Primary Central Nervous System Lymphoma
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT02836158
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
Acute Myeloid Leukemia, Myelodysplastic Syndromes
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.
- Trial name
- NCT04263181
- Testing
- Peripheral blood draw, Bone marrow aspirate, Buccal swab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Washington University School of Medicine
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002517
- Testing
- cytarabine, daunorubicin hydrochloride, dexamethasone
- Where
- 23 sites in Belgium, France and 1 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Relapsed Leukemia, Refractory Leukemia
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
This is a Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of chemotherapy combining with HLA-mismatched G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion as a…
- Trial name
- NCT07297173
- Testing
- Chemotherapy, HLA-mismatched GPBMC infusion, Allogeneic Stem Cell Transplantation
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Beijing 302 Hospital
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for…
- Trial name
- NCT00199056
- Testing
- Dexamethasone / Prednisolone, Cyclophosphamide, Methotrexate
- Where
- Germany
- Volunteers
- 225 people
- Sponsor
- Goethe University
Acute Myeloid Leukemia
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
In this multi-center, randomized, open-label, prospective clinical trial, a total of 60 relapsed/refractory AML patients will be randomized into 2 groups. In the experimental arm, patients receive IAC regimen.
- Trial name
- NCT02937662
- Testing
- Idarubicin, Cytarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination…
- Conditions
- Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT06034470
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
AML
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication…
- Trial name
- NCT02039726
- Testing
- Quizartinib, Salvage Chemotherapy
- Where
- 131 sites in United States, Australia and 17 more
- Volunteers
- 367 people
- Sponsor
- Daiichi Sankyo
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
This clinical trial studies idarubicin, cytarabine, and pravastatin sodium in treating patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01831232
- Testing
- pravastatin sodium, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myelogenous Leukemia
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625) to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used alone or in combination with Cytarabine…
- Trial name
- NCT00074737
- Testing
- cenersen, Idarubicin, Cytarabine
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- Eleos, Inc.
Myeloid Leukemia
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
Due to progressive therapy intensification in the four consecutive studies AML-BFM 78, 83, 93 and 98, prognosis for children with acute myeloid leukemia (AML) has improved steadily.
- Trial name
- NCT00111345
- Testing
- Anthracyclines, liposomal daunorubicin, 2-CDA
- Where
- Germany
- Volunteers
- 550 people
- Sponsor
- University Hospital Muenster
Pediatric Acute Myeloid Leukemia
Optimal Treatment Strategy Based on for Pediatric AML
The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)
- Trial name
- NCT02848183
- Testing
- Cytarabine, Idarubicin, Mitoxantrone
- Where
- 3 sites in South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Leukemia, Myeloid, Acute
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
The AML-12 study investigates the efficacy and toxicity of standard induction chemotherapy with idarubicin and cytarabine (IC) with G-CSF priming followed by a risk-adapted post remission therapy for patients up to the age of 70…
- Trial name
- NCT04687098
- Testing
- Idarubicin, Ara-C, G-CSF
- Where
- 15 sites in Spain
- Volunteers
- 1,034 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
The purpose of this study is to: Test the safety of the research study drug, lenalidomide, when given with Idarubicin and Cytarabine See how many respond to combination treatment with lenalidomide, Idarubicin and Cytarabine See…
- Trial name
- NCT00831766
- Testing
- Idarubicin, Cytarabine, Lenalidomide (Revlimid®)
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00093483
- Testing
- filgrastim, arsenic trioxide, cytarabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to…
- Trial name
- NCT00016159
- Testing
- filgrastim, lintuzumab, arsenic trioxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Promyelocytic Leukemia, Adult Acute
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all…
- Trial name
- NCT04897490
- Testing
- Evaluation of first line treatment with ATO/ATRA outcome
- Where
- 6 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda